Ipilimumab in patients with melanoma and autoimmune disease Journal Article


Authors: Kyi, C.; Carvajal, R. D.; Wolchok, J. D.; Postow, M. A.
Article Title: Ipilimumab in patients with melanoma and autoimmune disease
Abstract: Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies directed at CTLA-4 (ipilimumab), have excluded patients with underlying autoimmune disease given concern for potential triggering of autoimmune exacerbations. We present the first known cases to our knowledge of two patients with active autoimmune diseases who received ipilimumab. In this limited clinical experience, no serious exacerbations of underlying autoimmunity have yet been observed, and one patient benefited from ipilimumab. These cases advocate for further investigation of the safety of cancer immunotherapies in cancer patients with underlying autoimmune conditions in carefully designed clinical trials with cautious monitoring. © 2014 Kyi et al.; licensee BioMed Central Ltd.
Keywords: adult; human tissue; treatment response; aged; middle aged; prednisone; drug tolerability; fatigue; paresthesia; case report; cisplatin; paclitaxel; methotrexate; temozolomide; positron emission tomography; sentinel lymph node biopsy; carboplatin; ipilimumab; low drug dose; melanoma; computer assisted tomography; anemia; skin biopsy; weight reduction; vinblastine; immunotherapy; urine incontinence; celecoxib; rheumatoid arthritis; tumor growth; autoimmune diseases; autoimmune disease; multiple sclerosis; beta interferon; skin nodule; gamma secretase inhibitor; feces incontinence; inguinal region; knee pain; immune-related adverse events (iraes); human; male; female; priority journal; article; joint effusion
Journal Title: Journal for ImmunoTherapy of Cancer
Volume: 2
Issue: 1
ISSN: 2051-1426
Publisher: Biomed Central Ltd  
Date Published: 2014-10-14
Start Page: 35
Language: English
DOI: 10.1186/s40425-014-0035-z
PROVIDER: scopus
PMCID: PMC4207313
PUBMED: 25349698
DOI/URL:
Notes: Article -- Export Date: 5 June 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jedd D Wolchok
    905 Wolchok
  2. Richard D Carvajal
    148 Carvajal
  3. Michael Andrew Postow
    368 Postow